HOUSTON – The drug Semaglutide was initially marketed under the name Ozempic to manage type two diabetes.

Social media has nicknamed them “skinny pens” because they help people drop significant weight quickly, leading to the popularity and a shortage of both Ozempic and Wegovy.

The drug manufacturer Novo Nordisk confirms it’s struggling to meet demand and Houston patients, like Lauren Luman, say she doesn’t know what she’ll do.

Ozempic helped Luman lose weight and control her blood sugar.

However, endocrinologist Dr. Disha Narang, suggests there’s a need for successful weight loss drugs on the market.

According to the FDA, healthcare professionals can choose to prescribe drugs off-label when medically appropriate.